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Background: The use of systemic antifungal agents has increased in most tertiary care centers. However, antifungal
stewardship has deserved very little attention. Our objective was to assess the knowledge of European prescribing
physicians as a first step of an international program of antifungal stewardship.
Methods: Staff physicians and residents of 4 European countries were invited to complete a 20-point questionnaire
that was based on current guidelines of invasive candidiasis and invasive aspergillosis.
Results: 121 physicians (44.6% staff, 55.4% residents) from Spain 53.7%, Italy 17.4%, Denmark 16.5% and Germany
12.4% completed the survey. Hospital departments involved were: medical 51.2%, ICUs 43%, surgical 3.3% and
pharmaceutical 2.5%. The mean score of adequate responses (± SD) was 5.8 ± 1.7 points, with statistically significant
differences between study site and type of physicians. Regarding candidiasis, 69% of the physicians clearly
distinguished colonization from infection and the local rate of fluconazole resistance was known by 24%. The
accepted indications of antifungal prophylaxis were known by 38%. Regarding aspergillosis, 52% of responders
could differentiate colonization from infection and 42% knew the diagnostic value of galactomannan. Radiological
features of invasive aspergillosis were well recognized by 58% of physicians and 57% of them were aware of the
antifungal considered as first line treatment. However, only 37% knew the recommended length of therapy.
Conclusions: This simple, easily completed questionnaire enabled us to identify some weakness in the knowledge
of invasive fungal infection management among European physicians. This survey could serve as a guide to design
a future tailored European training program.
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Invasive fungal infections (IFIs), mainly invasive candidia-
sis (IC) and pulmonary aspergillosis (IPA), are a major
clinical problem due to its high morbidity and mortality
and affect many different patient populations cared by a
large number of physicians in tertiary care hospitals. The
difficulties for establishing a proven diagnosis, the better
tolerance of new antifungal drugs and the demonstrated
impact of early therapy have led to an extended use of em-
pirical antifungal therapies (AF), mainly in critical and sur-
gical patients. A recent cross sectional cohort study
showed that systemic antifungal therapy was administered* Correspondence: pmunoz@hggm.es
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unless otherwise stated.to 7% of all patients admitted to an intensive care unit
(ICU), with only one-third of them having a documented
IFI [1].
Previous studies have shown that inappropriate use of
antifungal drugs may reach 67-74% in tertiary care hospi-
tals [2-5]. The implementation of antifungal stewardship
policies based on first instances on continuous education
of healthcare workers may be a partial solution to this
problem [6]. However, there are no multicenter studies
evaluating the gaps in knowledge on diagnosis and treat-
ment of IFIs and on compliance with current guidelines in
European prescribing physicians.
The aim of this study was to assess knowledge of poten-
tial AF prescribers in order to design and apply operative
training strategies for European physicians, which willThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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appropriate use of antifungal agents.
Methods
Study design and setting
We performed a cross-sectional multicenter survey evaluat-
ing European prescribing physicians’ attitudes and know-
ledge about diagnosis and treatment of invasive candidiasis
and aspergillosis, and the compliance with current IFI
international guidelines [7-9]. Five European tertiary care
hospitals participated in the study: Hospital General
Universitario Gregorio Marañón, Madrid, Spain; University
Hospital of Heidelberg, Heidelberg, Germany; Rigshospitalet,
Copenhagen University Hospital, Denmark; Hospital “Sant’
Orsola-Malpighi” at Bologna, Italy and Hospital “Lazzaro
Spallanzani” at Rome, Italy. Hospital General Universitario
Gregorio Marañón served as the coordinating centre.
Attending physicians and residents, working in areas
typically associated with the largest consumption of
antifungal drugs (i.e. Hematology, Oncology, Internal
Medicine, Surgical wards and, ICUs), were invited to par-
ticipate to the survey. During the study period (February-
March 2013), a responsible investigator for each centre
(M.V.; M.H.; N.R.; P.V.; M.G.) personally invited all
physicians belonging to the departments with larger an-
tifungal consumption to answer the questionnaire. The
participation to the survey was voluntary and if the
physician agreed, they were given 20 minutes to
complete the test. The questionnaire was personally
collected and subsequently sent through email/fax to
the coordinating centre by responsible investigators.
No incentives were used to perform the survey and
consultation of any medical support (i.e. books, apps
and websites) was forbidden.
Questionnaire
According to current international guidelines [7-9], a
questionnaire was developed by the steering committee
of the Collaboration in Mycology Study Group (COMIC),
a multidisciplinary team including infectious disease
and clinical microbiology physicians, pharmacologist
and different medical and surgical specialities. The
questionnaire was anonymously completed and in-
cluded 20 multiple-choice questions assessing diagnosis
and management of IFI (see Additional file 1). Ques-
tions targeted to evaluate the inadequate indication of
antifungals, such as the clinical interpretation of posi-
tive cultures or current recommendations for pre-
emptive therapy, were specifically included. Each cor-
rect answer was scored as 0.5 points and each incorrect
answer as 0 points. Accordingly, the maximum score
was 10 points. We also collect information regarding
age, sex, department to which physicians belonged and
post- graduate years.In order to evaluate the readability, the comprehensibil-
ity, and the length, the survey was first tested among a
total of 20 physicians working at the Hospital General
Universitario Gregorio Marañón, Madrid. The study was
approved by the Ethics Committee of the coordinating
center (Comité ético de Investigación Clínica del Hospital
General Universitario Gregorio Marañón). Local centers
did not consider necessary further approval. Participating
physicians’s consent was obtained by local coordinators in
order to use the survey results for research purposes.
This study was partially supported by the PROMULGA
II Project, Instituto de Salud Carlos III (grant number
PI13/01148).
Statistical analysis
Our endpoint was the median knowledge score obtained
by the physicians prescribing antifungals in tertiary care
institutions. We also decided to compare the performance
of different groups of physicians (residents/fellows vs. staff
physicians, hospital department: ICUs, medical, surgical
and pharmaceutical departments) in the different coun-
tries. Haematology and oncology physicians were included
in the medical group. Not all physicians answered each
questions and, consequently numbers were adjusted as ap-
propriate for each question. The qualitative variables ap-
pear with their frequency distribution. The quantitative
variables are summarized as the mean and SD when they
had a normal distribution and median with range (mini-
mum-maximum) when they had a non-normal distribu-
tion. In order to compare how scores differ according to
participants’ characteristics we used the parametric t test or
the non-parametric ANOVA test. Multiple lineal regression
analysis was performed to detect differences in knowledge
between different departments, physician categories, and
country after adjusting by sex and postgraduate education.
Statistical significant was set at p ≤ 0.05. Statistical analysis
was made using SPSS® 18.0(SPSS, Chicago, IL, USA).
Results
One hundred and twenty-one physicians fulfilled the ques-
tionnaire. Demographic characteristics of participants and
mean score obtained according to sex, type of depart-
ments and country are summarized in Table 1. Mean age
and years of clinical practice after post-graduate education
of participating physicians were 36.5 and 10.6 respectively.
Overall, 54.5% of the physicians were women and the
mean score of adequate response was 5.8 ± 1.7 points.
When scores were compared according to different vari-
ables (Table 1) a higher significant mean score was associ-
ated with staff physicians (p = 0.01), medical departments
(p = 0.01) and with Italians respondents (p < 0.01).
The response rate to the different questions of the sur-
vey ranged from 85% to 100. The percentage of adequate
answers regarding departments and physician category
Table 1 Demographics characteristics of participants and
mean score obtained according to sex, type of
physicians, medical departments and country





<30 40 (33.1) 5.3 ± 1.4
≥30 81 (66.9) 6.1 ± 1.8 0.01
<40 75 (62) 5.3 ± 1.4 0.12
≥40 46 (38) 6.1 ± 1.8
Years of practice (mean ± SD)
<1 19 (15.8) 5 ± 0.9
≥1 102 (84.2) 6 ± 1.7 0.01
<5 33 (27.8) 5 ± 1.3 <0.001
≥5 88 (72.7) 6.2 ± 1.7
Sex
Female 66 (54.5) 5.9 ± 1.6 0.52
Male 55 (45.5) 5.7 ± 1.8
Physicians’ category
Residents 67 (55.4) 5.5 ± 1.6 0.01
Staff physicians 54 (44.6) 6.3 ± 1.8
Type of departments(a)
Medical 62 (51.2) 6.2 ± 1.9
Intensive care units 52 (43) 5.5 ± 1.4 0.01
Surgical 4 (3.3) 5.5 ± 1.5
Pharmaceutical 3 (2.5) 5.5 ± 0.5
Country(b)
Spain 65 (53.7) 5.6 ± 1.7
Italy 21 (17.4) 7.3 ± 1.4 <0.01
Denmark 20 (16.5) 5.0 ± 1.6
Germany 15 (12.4) 5.8 ± 1.1
(a)Although statistical differences in mean scores were not found between the
different departments in the simple linear regression analysis, they were found
between medical departments and the remaining 3 after adjusting for sex,
postgraduate education, and physician category. (b)Statistical differences in
mean scores were found between Italians responders and the other physicians
in the simple linear regression analysis. This difference remains after adjusting
for sex, post-graduate education and physician category.
Valerio et al. BMC Infectious Diseases  (2015) 15:80 Page 3 of 8for each question is showed in Table 2. In order to assess
differences between groups only medical and critical de-
partments were considered due to the low proportion of
surgeons and pharmaceutical physicians participating to
the survey. Overall, 13 out of 20 questions assessed
knowledge of candidiasis whereas 7 focused on diagnosis
and management of invasive aspergillosis.
Candidiasis
A low proportion of physicians clearly distinguished in-
fection from colonization both in the urinary tract
(69.4%) (Q1) and in the respiratory tract (42.1%) (Q2).The accepted indications of antifungal prophylaxis (Q3)
were known by 38% of the participants. However, the
majority of the physicians (88.4%) knew that fluconazole
is, in most of the cases, the recommended antifungal
agent for prophylaxis (Q4).
Regarding empirical therapy, only 41.3% of the physi-
cians were aware of the recommendation to initiate anti-
fungal therapy in a clinical scenario of sepsis with a
suspected portal of entry in a femoral catheter (Q5). Com-
paring the rate of adequate answers for Q5, statistical
differences could be detected both among different depart-
ments, as for physicians’ category. In fact, for the manage-
ment of such infection approximately one third of the
intensivists and staff clinicians would prescribe only em-
pirical treatment against gram positive and gram negative
bacteria, completely omitting anti-fungal coverage.
As for targeted therapy (Q6), 81.8% started treatment
immediately after knowing that yeast was recovered
from blood cultures, and 90.1% of the physicians choose
the correct/recommended antifungal treatment (Q7).
The majority of the prescribing physicians (75.2%)
could identify the specific characteristics of non-albicans
Candida species, including its potential for azole resist-
ance (Q8) and 83.5% recognized the need to consider in-
fectious endocarditis and endophtalmitis in a patient with
candidemia, and the importance of obtaining blood cul-
tures during the follow up in order to discard persistent
candidemia or treatment failure (Q9).
Sixty-four percent of physicians knew the correct
dosage of fluconazole (800 mg as loading dose followed
by 400 mg/day) (Q10), and the local rate of fluconazole re-
sistance was known only by 24% (it was generally overesti-
mated) (Q11). Finally, regarding the different indications
of liposomal amphotericin B (L-AmB), azoles or candins,
our questionnaire revealed that only 47.1% of the physi-
cians knew in which scenario L-AmB is the first choice
therapy for unspecified IFIs (Q12). A significant propor-
tion of clinicians considered L-AmB as the treatment of
choice for aspergillosis (26.5%) and for infections caused
by fluconazole-resistant Candida species (12%).
Sixty-eight percent answered correctly that candins
could be used as empirical treatment of candidemia before
knowing the antifungal susceptibility (Q13), but about
10% of respondents preferred voriconazole rather than
candins when treating infections due to fluconazole-
resistant Candida.
Invasive aspergillosis
Overall 52% of the physicians correctly differentiated re-
spiratory colonization from infection, but only 27% of
intensivists would start antifungal treatment if Aspergillus
spp. was recovered from a respiratory sample, taking into
account if the patients fulfilled criteria of proven or prob-
able invasive aspergillosis (p < 0.001) (Q14).
Table 2 Percentage of adequate answers regarding department and physician category
Question Adequate answer Overall Medical ICU P Residents Staff P
N = 121 n = 62 N = 52 n = 67 n = 54
Q1.When Candida is isolated in a urine
culture, choose the answer that best
describes what you would do:
Start antifungal treatment only in
some cases.
69.4 79 63.5 0.09 62.7 77.8 0.08
Q2.On a patient with mechanical
ventilation and a probable VAP a
tracheal aspirate culture shows
Candida sp. Which of the following
statements best show your
interpretation:
Requires antifungal treatment only if
the patient has a high Candida score.
42.1 46.5 38.5 0.44 38.8 46.3 0.46
Q3. In which of the following clinical
scenarios you would start Candida
prophylaxis?
AML (Acute Myeloid Leukemia)
patients on induction chemotherapy.
38 45.2 32.7 0.18 29.9 48.1 0.05
Q4.In your opinion, the best choice
for Candida prophylaxis is:.
Fluconazole in most of the cases. 88.4 83.9 92.3 0.25 85.1 92.6 0.25
Q5.In a patient with sepsis possibly
caused by a femoral catheter
infection, you would prescribe…
Treatment against Gram positive and
Gram negative bacteria and yeasts.
41.3 51.6 28.8 0.02 56.7 22.2 <0.001
Q6 .A microbiologist informs you
that there are yeasts at the gram
stain of a blood culture, so you…
Start antifungal treatment
immediately.
81.8 77.4 86.5 0.23 77.6 87 0.23
Q7.In a patient with candidemia,
which antifungal would be your first
choice before knowing the species
of Candida?
Candin or Fluconazole. 90.1 88.7 92.3 0.75 88.1 92.6 0.54
Q8 .Choose the right answer among
the following statements:
All of the above are true: Candida
glabrata can be resistant to
fluconazole. Candida krusei is always
resistant to fluconazole. Candida
parapsilosis is associated to catheter
infection. Candida albicans is usually
susceptible to fluconazole.
75.2 75.8 73.1 0.83 73.1 77.8 0.67
Q9.During the follow-up of candidemic
patients, it is advised to:
All of the above are true: Draw




perform an eye fundus examination;
consider sequential treatment
switching to an oral azole when
clinically safe.
83.5 85.5 80.8 0.61 80.6 87 0.46
Q10. In the treatment of candidemia
by a fluconazole-susceptible Candida,
you would usually prescribe:
Fluconazole 400 to 800 mg per day
depending on the Candida species.
64.5 74.2 53.8 0.03 62.7 66.7 0.7
Q11.Which do you think is the
percentage of fluconazole resistance
in Candida strains isolated from
blood cultures at your hospital?
Less than 5%. 24 19.4 28.8 0.27 23.9 24.1 1
Q12.In which of the following
scenarios would you choose L-AmB
as your first choice?
In unspecified invasive filamentous
fungal infection.
47.1 51.6 44.2 0.45 35.8 61.1 <0.006
Q13. Regarding the treatment with
azoles and candins, which of the
following statements is true:
Candins can be used as empirical
treatment before knowing the yeast
antifungal susceptibility.
67.8 64.5 75 0.30 53.7 85.2 <0.001
Q14.When isolating Aspergillus spp.
in a respiratory sample, you would
consider:
Treatment in patients who fulfilled
criteria of proven or probable
invasive aspergillosis
52.1 74.2 26.9 <0.01 49.3 55.6 0.58
Q15.Which of the following
statements regarding the
Galactomannan test is false:
It can only be performed in serum
samples.
42 50.8 35.3 0.13 36.9 48.1 0.26
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Table 2 Percentage of adequate answers regarding department and physician category (Continued)
Q16.Which of the following are
considered invasive aspergillosis
radiological findings?
All of the above are true: Presence of
dense, well-circumscribed lesions with
or without a halo sign in a thoracic CT
scanner; presence of a cavity in a
thoracic CT scanner; presence of an
air-crescent sign in a thoracic CT
scanner; sinusitis.
58.7 67.7 51.9 0.12 59.7 57.4 0.85
Q17.In a patient with invasive
pulmonary aspergillosis, which
antifungal treatment would you
choose before having the antifungal
susceptibility data?
Voriconazole 57 56.5 61.5 0.70 43.3 74.1 <0.001
Q18.In your opinion, which are the
indications of combined antifungal
therapy in invasive aspergillosis?
It is recommended as rescue therapy
when previous antifungal treatment
has failed.
38.8 43.5 30.8 0.17 32.8 46.3 0.14
Q19.What is your opinion concerning
the measurement of antifungal
levels?
All of the above are true: Up-to-date
guidelines do not recommend its
systematical determination; it can be
useful to identify azoles under-dosed
patients; there is no indication to
determine serum levels of L-AmB; it
can help to identify azoles related
toxicity.
62 67.7 55.8 0.24 56.7 68.5 0.19
Q20.In your opinion, which would be
the proper length of treatment of
aspergillosis in a solid organ
recipient
A minimum of 6 to 12 weeks. 36.7 37.1 33.3 0.7 34.8 38.9 0.7
VAP (Ventilator Associated Pneumonia).
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quainted with the use of galactomannan assay as a
diagnostic and follow up test (Q15), and more than half
of the physicians (58.5%) recognized the radiological
features of IA (Q16).
Concerning therapy (Q17), 57% of the physicians were
aware that voriconazole was the first line IA treatment.
Many physicians believed that combined antifungal ther-
apy with L-AmB and voriconazole (13.3%) or with vori-
conazole and caspofungin (11.5%) was accepted as first
line therapy for treating IA. L-AmB was believed to be
the drug of choice by 14.1% of the physicians (3.5%
10 mg/kg/day and 10.6% 3 mg/kg/day). When asked spe-
cifically on the indications of combined treatment for
IA, 29% considered it appropriate as initial therapy of
neutropenic patients or transplant recipients, and 38.8%
only for rescue therapy (Q18).
More than half of physicians (62%) were aware of the
clinical benefits of measuring voriconazole and posacona-
zole plasma levels during patient treatment (Q19) and fi-
nally, the recommended length of therapy for IA according
to current guidelines was only known by 36.7% of the phy-
sicians – 29% wrongly considered that 4 to 6 weeks were
enough to treat most IA episodes (Q20).
Discussion
We report the first multicenter European study assessing
physicians’ knowledge about current recommendationson diagnosis and treatment of IFI. We could demonstrate
that even frequent prescribers have a significant need of
continuous education. Most common mistakes lead to an-
tifungal over consumption, since many physicians errone-
ously treat fungal colonization, use unnecessary high
doses of L-AmB and administered combined antifungal
therapy with no supporting scientific evidence.
Our survey corroborates gaps in both diagnosis and
management of IFI in 5 institutions of 4 European coun-
tries. Physicians have problems for differentiating
colonization from infection when Candida spp. is iso-
lated in urine or in a tracheal aspirate, which could lead
to an over prescription of antifungals. In a prospective
study conducted in a Thai tertiary care setting, Sutepvarnon
et al. demonstrated a positive correlation between isolation
of Candida species from urine and unnecessary treatment
[5]. Other common scenario of avoidable over treatment is
the isolation of Candida in respiratory secretions which
should not be the only indication for starting antifungal
therapy [7,10].
Another aspect deserving attention is the lack of know-
ledge of the current indications of antifungal prophylaxis
and empirical treatment for invasive candidiasis. Almost
50% of physicians would initiate Candida prophylaxis in
every ICU patient colonized by Candida spp. or in the
clinical scenario of an ICU patient having an urinary in-
dwelling catheter, central venous catheter and recent sur-
gery, without taking into consideration other risk factors
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adequate management could be related to the results of at
least four prospective studies of ICU and surgical patients
suggesting a reduction in Candida infection and mortality
under fluconazole prophylaxis [11-14]. However, since the
universal administration of antifungal prophylaxis remains
an inefficient strategy that may increase subsequent azole-
resistance or non-albicans candidemia [15-17], it is cur-
rently warranted only in selected ICU patients at highest
risk (>10%) of invasive candidiasis [7,18].
On the other hand, we observed a partial impact on med-
ical practice of the articles demonstrating the importance
of an early initiation of targeted antifungal treatment
when there is a clinical suspicion of invasive candidiasis
[19-21]. Unfortunately, about 20% of physicians delay the
start of antifungal treatment after being informed of posi-
tive blood cultures, whereas the critical window of oppor-
tunity for antifungal initiation appears to be 12–24 hours
following the first positive blood cultures were drawn
[20,22]. Moreover, we reported that 60% of physicians
(staff more frequently than residents and intensivists more
frequently than medical physicians) failed to identify the
indications of antifungal treatment in patients with suspi-
cion of catheter related infection [23].
However, the clinical outcome in IFI related sepsis is
not only related to adequacy and timeliness of antifungal
administration, but also on appropriate dosing, all these
factors associated with length of hospital stay, health
care costs, morbidity and mortality [20,22,24]. We found
that another critical point regarding knowledge of
Candida infections management is the appropriate
fluconazole dosage, that was correctly known by only
62% of the physicians. In a retrospective cohort study
performed by Labelle et al., inadequate initial flucona-
zole dose was prescribed in about half of the critical pa-
tients with invasive candidiasis and it was associated
with an increased risk of in-hospital mortality [25]. In-
deed, failure to achieve pharmacodynamic targets for
fluconazole has been associated with worse outcomes
[26-29]. For this reason, to obtain clinical success, dose
of fluconazole should be tailored to achieve AUC/MIC
ratios of at least 25 (using Clinical and Laboratory
Standards Institute MIC methodology) [30] or 100
(using European Committee on Antimicrobial Suscepti-
bility Testing MIC methodology). These targets usually
require 6 mg/kg/day (following 12 mg/kg loading) for
susceptible isolates or 12 mg/kg/day for C. glabrata or
other isolates with MICs of 16-32 mg/L [7].
Most physicians were not aware of their local inci-
dence of azoles resistance in Candida, which could en-
hance the prescription of broad-spectrum antifungals.
Although non-albicans strains have clearly increased, in
many European centers the rate of fluconazole resistance
is still less than 5% [31-34].More surprisingly to us was to find that 12% and 9.2%
of physicians would select L-AmB and voriconazole, re-
spectively, instead of a candin to treat these fluconazole-
resistant Candida infections. L-AmB should be restricted
to selected cases of intra-abdominal candidiasis [35,36] or
intolerance to other antifungal agents due to its potential
toxicity and higher cost, and voriconazole should be lim-
ited to step-down oral therapy for selected cases of can-
didiasis due to C. krusei or voriconazole-susceptible C.
glabrata [7]. Finally, we would like to stress that there are
differences among published guidelines regarding some
diagnostic and therapeutic aspects of candidiasis that need
to be clarified for the sake of a more clear understanding
by the prescribing physicians [37].
Regarding IA, problems to differentiate colonization
from infection were also evident. As previously demon-
strated only 22.3% of Aspergillus isolates from respira-
tory tract corresponds to probable/proven IA episodes.
For this reason, Bouza et al. proposed a prediction score
taking into account the procedure used to obtain the
sample, the presence of leukaemia, neutropenia or the
use of corticoids to help clinicians in the interpretation
of Aspergillus cultures [38].
Another problem was that a high percentage of the
prescribing physicians still consider L-AmB as the first
line therapy for IA, whereas the largest prospective,
randomized trial for the treatment of IA demonstrated
that voriconazole was superior to D-AmB [8,39]. Fur-
thermore, 3.5% of the physicians continue to believe that
high doses of L-AmB are necessary to treat IA, ignor-
ing the results of the AmBiLoad Trial [40,41]. The effi-
cacy of voriconazole was further demonstrated in
paediatric and adult patients receiving voriconazole for
treatment of IA who were refractory or intolerant to
conventional antifungal therapy [8,39,42,43]. The role of
combination therapy as primary or salvage therapy is
uncertain and it is not actually recommended in inter-
national guidelines [8].
The majority of physicians ignored that current guide-
lines recommend that treatment of IA should be contin-
ued for a minimum of 6–12 weeks and that voriconazole
plasma levels should be monitored during treatment to
avoid toxicity and therapeutic failure [44-47].
Finally, we found differences in knowledge between
experimented physicians and residents. As we expected,
the haematologists and infectious disease specialists
(medical departments), are more proficient in the use of
antifungal therapy. However, ICU physicians that are
directly responsible for many pre-emptive and empirical
antifungal prescriptions did not score so well compara-
tively. Interestingly, Apisarnthanarak et al. reported that
44% and 31% of inappropriate antifungal use was de-
tected in medical departments and ICUs respectively,
and 15% in surgical departments [4].
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tion of physicians that more frequently prescribe antifun-
gal agents and the hospitals for the questionnaire. This
means that the results could be worse if all the physicians
of all institutions had been offered to participate. We also
included a heterogeneous group of physicians who are
mainly involved in different fields of IFI infection and only
addressed knowledge in Candida and Aspergillus invasive
infections. Finally, although the response rate to different
questions was high (85-100%), potential bias could result
due to non-response to specific questions.
Given the findings of our study assessing the basal
knowledge of antifungal prescribers in 5 European insti-
tutions, operative attempts to ameliorate the inappropri-
ate use of medications should be performed. We believe
that these European interventions should be based on:
1) Educational programs focusing on correct drugs and
dose administration of antifungals; 2) Improvement in
appropriate clinical interpretation of fungal isolates; 3)
Establishment of antifungal management programs that
incorporate infectious diseases specialists that as previ-
ously documented [5,48] are important in order to im-
prove quality of care while optimizing hospital costs and
antifungal use.
Conclusions
In conclusion, a simple survey enabled us to assess the
knowledge and practice of European prescribing physi-
cians in important aspects of diagnosis, prophylaxis and
antifungal treatment of IFIs. This study has revealed that
there are serious lacks in knowledge in this area that re-
quires a tailored educational program as a first step of
an international antifungal stewardship implementation.
Additional file
Additional file 1: Consists in the 20- point survey administered to
participants.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Design of the study: PM, EB. Data retrieval: MV, AV, EB, NR, PV, MH, MG, PM.
Data analysis: MV, AV, EB, NR, PV, MH, MG, PM. Writing of the manuscript: MV,
AV, PM, EB. Approval of final manuscript: all authors.
Acknowledgements
We would like to thank the entire COMIC study group (Collaborative group
on Mycosis). Melanie Adda, Roberto Alonso, Fernando Anaya, Rafael Bañares,
Emilio Bouza, Amaya Bustinza, Betsabé Cáliz, Ana Fernández-Cruz, Pilar
Escribano, Lorenzo Fernández-Quero, Isabel Frias, Jorge Gayoso, Paloma
Gijón, Jesús Guinea, Javier Hortal, Marta Kestler, Maria del Carmen Martínez,
Iván Márquez, Patricia Muñoz, Belén Padilla, Teresa Peláez, José Peral, Blanca
Pinilla, Diego Rincón, Carmen Guadalupe Rodríguez, Magdalena Salcedo,
Carlos Sánchez, Mar Sánchez-Somolinos, Maria Sanjurjo, David Serrano,
Maricela Valerio, Eduardo Verde, Encarnación Vilalta, and Elena Zamora.Fundings
This study was partially financed by PROMULGA Project. Instituto de Salud
Carlos III. PI1002868.
Author details
1Department of Clinical Microbiology and Infectious Diseases, Hospital
General Universitario Gregorio Marañón, Madrid, Spain. 2Instituto de
Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 3Department of
Medicine, Facultad de Medicina, Universidad Complutense de Madrid,
Madrid, Spain. 4Intensive Care Unit, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark. 5Department of Medical and Surgical
Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of
Bologna, Bologna, Italy. 6Department of Anesthesiology and Intensive Care
Medicine, University Hospital of Heidelberg, Heidelberg, Germany.
Received: 9 June 2014 Accepted: 6 February 2015References
1. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al.
Systemic antifungal therapy in critically ill patients without invasive fungal
infection*. Crit Care Med. 2012;40(3):813–22.
2. Valerio M, Rodriguez-Gonzalez CG, Munoz P, Caliz B, Sanjurjo M, Bouza E.
Evaluation of antifungal use in a tertiary care institution: antifungal
stewardship urgently needed. J Antimicrob Chemother. 2014;69(7):1993–9.
3. Nivoix Y, Launoy A, Lutun P, Moulin JC, Phai Pang KA, Fornecker LM, et al.
Adherence to recommendations for the use of antifungal agents in a
tertiary care hospital. J Antimicrob Chemother. 2012;67(10):2506–13.
4. Apisarnthanarak A, Yatrasert A, Mundy LM. Impact of education and an
antifungal stewardship program for candidiasis at a Thai tertiary care center.
Infect Control Hosp Epidemiol. 2010;31(7):722–7.
5. Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ.
Inappropriate use of antifungal medications in a tertiary care center in
Thailand: a prospective study. Infect Control Hosp Epidemiol.
2008;29(4):370–3.
6. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP,
et al. Infectious Diseases Society of America and the Society for Healthcare
Epidemiology of America guidelines for developing an institutional
program to enhance antimicrobial stewardship. Clin Infect Dis.
2007;44(2):159–77.
7. Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK, Calandra TF, Edwards Jr
JE, et al. Clinical practice guidelines for the management of candidiasis:
2009 update by the Infectious Diseases Society of America. Clin Infect Dis.
2009;48(5):503–35.
8. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA,
et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious
Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.
9. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O,
et al. ESCMID* guideline for the diagnosis and management of Candida
diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect.
2012;18 Suppl 7:19–37.
10. El-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J,
et al. Significance of the isolation of Candida species from respiratory
samples in critically ill, non-neutropenic patients. An immediate postmortem
histologic study. Am J Respir Crit Care Med. 1997;156(2 Pt 1):583–90.
11. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al.
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk
surgical patients. Crit Care Med. 1999;27(6):1066–72.
12. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D.
Prevention of severe Candida infections in nonneutropenic, high-risk,
critically ill patients: a randomized, double-blind, placebo-controlled trial in
patients treated by selective digestive decontamination. Intensive Care Med.
2002;28(12):1708–17.
13. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves
survival in septic shock: a randomized double-blind prospective study.
Crit Care Med. 2003;31(7):1938–46.
14. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J,
et al. Double-blind placebo-controlled trial of fluconazole to prevent
candidal infections in critically ill surgical patients. Ann Surg.
2001;233(4):542–8.
Valerio et al. BMC Infectious Diseases  (2015) 15:80 Page 8 of 815. Playford EG, Eggimann P, Calandra T. Antifungals in the ICU. Curr Opin
Infect Dis. 2008;21(6):610–9.
16. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al.
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates
and death. J Antimicrob Chemother. 2010;65(5):1042–51.
17. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M,
Hernandez-Caballero C, Aznar-Martin J, et al. Risk factors for fluconazole-
resistant candidemia. Antimicrob Agents Chemother. 2010;54(8):3149–54.
18. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V,
et al. Multicenter retrospective development and validation of a clinical
prediction rule for nosocomial invasive candidiasis in the intensive care
setting. Eur J Clin Microbiol Infect Dis. 2007;26(4):271–6.
19. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of
inappropriate antimicrobial therapy results in a fivefold reduction of survival
in human septic shock. Chest. 2009;136(5):1237–48.
20. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida
bloodstream infection until positive blood culture results are obtained: a
potential risk factor for hospital mortality. Antimicrob Agents Chemother.
2005;49(9):3640–5.
21. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed
to Candida infection: importance of empiric therapy and source control.
Clin Infect Dis. 2012;54(12):1739–46.
22. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to
initiation of fluconazole therapy impacts mortality in patients with
candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.
23. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical
practice guidelines for the diagnosis and management of intravascular
catheter-related infection: 2009 Update by the Infectious Diseases Society of
America. Clin Infect Dis. 2009;49(1):1–45.
24. Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al.
Inappropriate empiric antifungal therapy for candidemia in the ICU and
hospital resource utilization: a retrospective cohort study. BMC Infect Dis.
2010;10:150.
25. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors
for hospital mortality in Candida bloodstream infections. Crit Care Med.
2008;36(11):2967–72.
26. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and
the fluconazole dose/MIC ratio correlate with therapeutic response among
patients with candidemia. Antimicrob Agents Chemother. 2005;49(8):3171–7.
27. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the
concentration-time curve/MIC and dose/MIC ratios with mortality in
nonneutropenic patients with candidemia. Antimicrob Agents Chemother.
2007;51(1):35–9.
28. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of
fluconazole pharmacodynamics with mortality in patients with candidemia.
Antimicrob Agents Chemother. 2008;52(9):3022–8.
29. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, Laguna F, Donnelly JP,
Mouton JW, et al. Correlation of the MIC and dose/MIC ratio of fluconazole
to the therapeutic response of patients with mucosal candidiasis and
candidemia. Antimicrob Agents Chemother. 2007;51(10):3599–604.
30. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for
fluconazole and Candida revisited: a blueprint for the future of antifungal
susceptibility testing. Clin Microbiol Rev. 2006;19(2):435–47.
31. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R.
Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob
Agents. 2006;27(5):359–66.
32. Guinea J, Pelaez T, Rodriguez-Creixems M, Torres-Narbona M, Munoz P,
Alcala L, et al. Empirical treatment of candidemia in intensive care units:
fluconazole or broad-spectrum antifungal agents? Med Mycol.
2009;47(5):515–20.
33. Munoz P, Fernandez-Turegano CP, Alcala L, Rodriguez-Creixems M, Pelaez T,
Bouza E. Frequency and clinical significance of bloodstream infections
caused by C albicans strains with reduced susceptibility to fluconazole.
Diagn Microbiol Infect Dis. 2002;44(2):163–7.
34. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin
and triazole antifungal susceptibility profiles for clinical opportunistic yeast
and mold isolates collected from 2010 to 2011: application of new CLSI
clinical breakpoints and epidemiological cutoff values for characterization of
geographic and temporal trends of antifungal resistance. J Clin Microbiol.
2013;51(8):2571–81.35. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J,
Kett DH, et al. A research agenda on the management of intra-abdominal
candidiasis: results from a consensus of multinational experts. Intensive Care
Med. 2013;39(12):2092–106.
36. Pea F. Current pharmacological concepts for wise use of echinocandins in
the treatment of Candida infections in septic critically ill patients. Expert Rev
Anti Infect Ther. 2013;11(10):989–97.
37. Deshpande A, Gaur S, Bal AM. Candidaemia in the non-neutropenic patient:
a critique of the guidelines. Int J Antimicrob Agents. 2013;42(4):294–300.
38. Bouza E, Guinea J, Pelaez T, Perez-Molina J, Alcala L, Munoz P. Workload due
to Aspergillus fumigatus and significance of the organism in the microbiology
laboratory of a general hospital. J Clin Microbiol. 2005;43(5):2075–9.
39. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann
JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive
aspergillosis. N Engl J Med. 2002;347(6):408–15.
40. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al.
Liposomal amphotericin B as initial therapy for invasive mold infection: a
randomized trial comparing a high-loading dose regimen with standard
dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–97.
41. Munoz P, Guinea J, Narbona MT, Bouza E. Treatment of invasive fungal
infections in immunocompromised and transplant patients: AmBiLoad trial
and other new data. Int J Antimicrob Agents. 2008;32 Suppl 2:S125–31.
42. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al.
Voriconazole compared with liposomal amphotericin B for empirical
antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med. 2002;346(4):225–34.
43. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros
J, et al. Voriconazole treatment for less-common, emerging, or refractory
fungal infections. Clin Infect Dis. 2003;36(9):1122–31.
44. Smith J, Andes D. Therapeutic drug monitoring of antifungals:
pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit.
2008;30(2):167–72.
45. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole
therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf.
2010;9(1):125–37.
46. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al. Challenging
recommended oral and intravenous voriconazole doses for improved
efficacy and safety: population pharmacokinetics-based analysis of adult
patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–90.
47. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole
therapeutic drug monitoring in patients with invasive mycoses improves
efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.
48. McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, Scull JA, Martinelli LP.
The value of infectious diseases specialists: non-patient care activities.
Clin Infect Dis. 2008;47(8):1051–63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
